Theravance-GSK's Relvar is backed for approval in EU for asthma, COPD

09/20/2013 | Reuters

The European Medicines Agency endorsed the approval of GlaxoSmithKline and Theravance's Relvar as a treatment for asthma and chronic obstructive pulmonary disease. The inhaled drug, marketed as Breo in the U.S., is a combination of corticosteroid and a long-acting beta-agonist. A final decision is expected in the next quarter.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC